LI-RADS:回顾与展望
本文回顾了LI-RADS自2011年发布以来的发展,从单一CT/MRI细胞外对比剂诊断HCC的算法扩展为覆盖所有主要肝脏影像模态和应用场景的多算法网络,并制定了词典、报告模板和补充材料。文章总结了其全球临床与研究应用及美国HCC诊断系统的统一,讨论了监测、诊断人群定义、LR-5敏感性有限、不确定观察的管理、报告挑战及治疗后反应评估等不足,并展望了基于概率和整合定量影像特征的未来方向。
要点
- LI-RADS已发展为覆盖所有主要肝脏影像模态的多算法网络,包含词典和报告模板。
- LR-5(明确HCC) category敏感性有限,不确定观察的管理存在挑战。
- 未来方向为整合患者特征和定量影像特征的基于概率的诊断与预后系统。
核心结论
- LI-RADS已从单一HCC诊断算法发展为多算法网络,未来将转型为基于概率的肝癌诊断与预后系统。
研究设计与样本
- 本文为综述,回顾LI-RADS自2011年发布后11年的发展,未报告系统检索范围与纳入文献数量。
诊断标准与关键数值
- LI-RADS最初为采用细胞外对比剂CT或MRI诊断HCC的单一算法。
- LR-5 category代表明确HCC,原文提及该category敏感性有限。
临床应用与阅片要点
- 日常阅片应使用LI-RADS词典和报告模板,注意LR-5敏感性有限及不确定观察的管理。
- 治疗后反应评估需关注放射治疗和系统治疗后的挑战。
局限性
- 原文指出当前存在监测、诊断人群定义、感知复杂性、LR-5敏感性有限、不确定观察管理、报告及治疗后反应评估等知识缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Since its initial release in 2011, the Liver Imaging Reporting and Data System (LI-RADS) has evolved and expanded in scope. It started as a single algorithm for hepatocellular carcinoma (HCC) diagnosis with CT or MRI with extracellular contrast agents and has grown into a multialgorithm network covering all major liver imaging modalities and contexts of use. Furthermore, it has developed its own lexicon, report templates, and supplementary materials. This article highlights the major achievements of LI-RADS in the past 11 years, including adoption in clinical care and research across the globe, and complete unification of HCC diagnostic systems in the United States. Additionally, the authors discuss current gaps in knowledge, which include challenges in surveillance, diagnostic population definition, perceived complexity, limited sensitivity of LR-5 (definite HCC) category, management implications of indeterminate observations, challenges in reporting, and treatment response assessment following radiation-based therapies and systemic treatments. Finally, the authors discuss future directions, which will focus on mitigating the current challenges and incorporating advanced technologies. Tha authors envision that LI-RADS will ultimately transform into a probability-based system for diagnosis and prognostication of liver cancers that will integrate patient characteristics and quantitative imaging features, while accounting for imaging modality and contrast agent.
引用
- Chernyak, Fowler, Do, et al. LI-RADS: Looking Back, Looking Forward. Radiology. 2023. PMID: 36853182. doi:10.1148/radiol.222801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。